[Form 4] ANI PHARMACEUTICALS INC Insider Trading Activity

Rhea-AI Filing Summary

Meredith W. Cook, Senior Vice President, General Counsel & Secretary of Ani Pharmaceuticals (ANIP), reported a sale of 400 shares of the company on 09/12/2025 at a price of $98.42 per share. After the transaction she beneficially owned 76,074 shares. The filing states the sale was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on 09/17/2024, indicating the trade followed an automated plan rather than an ad‑hoc decision. The Form 4 was signed by Ms. Cook on 09/15/2025.

Insights

Corporate Governance Expert

TL;DR: A small, pre-planned insider sale executed under a 10b5-1 plan, signalling routine liquidity rather than a governance red flag.

The transaction is a disposal of 400 shares at $98.42 under a Rule 10b5-1 plan adopted in September 2024. Use of a 10b5-1 plan typically reduces information asymmetry because trades follow pre-set parameters. The remaining stake of 76,074 shares is disclosed, preserving transparency about ongoing ownership. No other material changes to role or compensation are disclosed.

Securities Analyst

TL;DR: Transaction size is small relative to disclosed holdings and executed under a prior plan, so market impact is likely minimal.

The sale of 400 shares represents a minor reduction in beneficial ownership and was executed under an established 10b5-1 trading plan, reducing concerns about opportunistic timing. The Form 4 provides exact figures for shares sold, price, and post-transaction ownership, enabling straightforward updates to insider-holding records. No new derivative activity or additional material disclosures are included.

09/15/2025 - 07:16 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Cook Meredith

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SR. VP, GENERAL COUNSEL & SEC.

3. Date of Earliest Transaction (Month/Day/Year)
09/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/12/2025		S(1)		400	D	$98.42	76,074	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2024.

Remarks:

	/s/ Meredith W. Cook	09/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Meredith W. Cook report for ANIP?

She reported a sale of 400 shares of Ani Pharmaceuticals on 09/12/2025 at $98.42 per share.

How many ANIP shares does Meredith Cook own after the reported sale?

Following the transaction she beneficially owned 76,074 shares.

Was the sale by the reporting person part of a pre-planned program?

Yes. The Form 4 states the sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 09/17/2024.

When was the Form 4 signed and filed?

The signature block shows the form was signed by Meredith W. Cook on 09/15/2025.

Did the Form 4 disclose any derivative transactions or amendments?

No. The filing lists only a non-derivative sale of common stock; no derivative transactions or amendments are disclosed.